Changing medicine with a new generation of PULMONARY-DELIVERED THERAPEUTICS PULMATRiX is pioneering patient care, expanding horizons for people with serious disease. ©2021 PULMATRiX, Inc. Produced in the USA. Terms of UsePrivacy StatementContact Us

Events & Presentations Investor Presentation Investor Alerts 2014 2015 2016 2017 2018 2019 2020 2021 January February March April May June July August September October November December All Categories Home GO Upcoming Events Past Events Loading Events... 2021 PULMATRiX, Inc. Produced in the USA. Terms of UsePrivacy StatementContact Us

Committee Charters | Management Team Corporate Governance Audit Committee Charter (214 KB) Executive Compensation Committee Charter (122 KB) Nominating & Governance Committee Charter (130 KB) Code of Conduct and Whistleblower Policy (469 KB) 2021 PULMATRiX, Inc. Produced in the USA. Terms of UsePrivacy StatementContact Us

Publications As we advance our mission to develop breakthrough therapies that fundamentally change the way we treat, prevent, and control progressive and infectious respiratory diseases, we regularly share the progress of our research. To learn more about our science and research findings, download the PDFs below: ACAAI – 2018 – A Phase 1/1B Study of an Inhaled Formulation of Itraconazole in Healthy Volunteers and Asthmatics (1.2 MB) ERS – 2018 – PUR1800 (RV1162), A Novel Narrow Spectrum Kinase Inhibitor, but Not Fluticasone, Reduces TNFα-Induced Cytokine Release by Primary Bronchial Epithelial Cells from Healthy Volunteers and COPD Patients (5.6 MB) ATS – 2018 – The Effect of RV1162 (PUR1800), A Novel Narrow Spectrum Kinase Inhibitor, on Viral Replication and Viral-Induced Inflammation in Primary Human Airway Cells (696 KB) AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF (200 KB) NACFC – 2017 – Systemic and Pulmonary Exposure of PUR1900 Following Inhalation Dosing in Rats and Dogs Over 28 Days / PDF (3 MB) RDD 2014 - Levofloxacin Dry Powders Engineered for Efficient Pulmonary Delivery and Stability / PDF (238 KB) RDD 2012 — Development of an iSPERSE™ Based Platform for the Delivery of Macromolecules via Dry Powder Formulations / PDF (633 KB) RDD 2012 — Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology / PDF (287 KB) A Novel Inhaled Dry Powder Delivery Platform for the Delivery of Large Molecule Drugs to the Lung for Local and Systemic Treatments / PDF (108 KB) RDD Europe 2011 - iSPERSE™: Formulation and In Vitro Characterization of a Novel Dry Powder Drug Delivery Technology / PDF (149 KB) ATS 2011 — Efficacy of Fluticasone and Salmeterol in a Novel Inhaled Dry Powder Delivery Platform / PDF (134 KB) ISAM 2011 Conference abstract — Deposition of Aerosolized Liquid Formulation in Ferrets by 3D CT / Spect Imaging / PDF (134 KB) ISAM 2011 Conference abstract — A Novel Inhaled Dry Powder Delivery Platform; Efficacy of Fluticasone and Salmeterol During Allergic Asthm / PDF (125 KB) 2021 PULMATRiX, Inc. Produced in the USA. Terms of UsePrivacy StatementContact Us